After ChatGPT debuted in late 2022 and GPT-4 hit the scene in March of the following year, many executives at pharma companies sat up and took note, interested in new tech that could accelerate the stubbornly slow drug development process. Translating that vision into reality, however, is not straightforward and a significant number of pharma…